Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) EBIT: 2014-2024

Historic EBIT for Voyager Therapeutics (VYGR) over the last 11 years, with Dec 2024 value amounting to -$83.3 million.

  • Voyager Therapeutics' EBIT fell 122.02% to -$30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.2 million, marking a year-over-year decrease of 1645.02%. This contributed to the annual value of -$83.3 million for FY2024, which is 168.26% down from last year.
  • As of FY2024, Voyager Therapeutics' EBIT stood at -$83.3 million, which was down 168.26% from $122.0 million recorded in FY2023.
  • In the past 5 years, Voyager Therapeutics' EBIT registered a high of $122.0 million during FY2023, and its lowest value of -$83.3 million during FY2024.
  • Its 3-year average for EBIT is -$4.0 million, with a median of -$50.8 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 368.84% in 2021, then spiked by 340.01% in 2023.
  • Yearly analysis of 5 years shows Voyager Therapeutics' EBIT stood at $27.4 million in 2020, then plummeted by 368.84% to -$73.6 million in 2021, then skyrocketed by 30.94% to -$50.8 million in 2022, then skyrocketed by 340.01% to $122.0 million in 2023, then tumbled by 168.26% to -$83.3 million in 2024.